Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2024 Nov;25(11):e13811.
doi: 10.1111/obr.13811. Epub 2024 Aug 12.

Safety and efficacy of glucagon-like peptide-1 (GLP-1) receptor agonists in patients with weight regain or insufficient weight loss after metabolic bariatric surgery: A systematic review and meta-analysis

Ali Esparham  1 , Ali Mehri  2 , Amin Dalili  3 , Jesse Richards  4 , Zhamak Khorgami  5   6
Affiliations
Meta-Analysis

Safety and efficacy of glucagon-like peptide-1 (GLP-1) receptor agonists in patients with weight regain or insufficient weight loss after metabolic bariatric surgery: A systematic review and meta-analysis

Ali Esparham et al. Obes Rev. 2024 Nov.

Abstract

Introduction: Weight regain and insufficient weight loss are major challenges after metabolic bariatric surgery (MBS), affecting patients' comorbidities and quality of life. The current systematic review and meta-analysis aim to assess the efficacy and safety of GLP-1 receptor agonists (GLP-1 RA) in patients with weight regain or insufficient weight loss after MBS.

Methods: A systematic search was conducted across PubMed, Embase, Scopus, and Web of Science databases to find the relevant studies.

Results: A total of 19 articles were included. The highest doses of liraglutide and semaglutide were 3 mg per day and 1 mg once weekly, respectively, in the included studies. The mean differences in weight and body mass index after treatment were -7.02 kg or 3.07 kg/m2, -8.65 or -5.22 kg/m2, and -6.99 kg or -3.09 kg/m2 for treatment durations of ≤ 6 months, 6-12 months, and >12 months with liraglutide, respectively. Additionally, weekly semaglutide showed significantly greater weight loss compared to daily liraglutide, with a mean difference of 4.15 kg. Common complications included nausea (19.1%), constipation (8.6%), abdominal pain (3.7%), and vomiting (2.4%).

Conclusion: Using GLP-1 RA is a safe and effective treatment for weight regain and insufficient weight loss after MBS.

Keywords: Liraglutide; Semaglutide; bariatric surgery; glucagon‐like peptide 1; insufficient weight loss; morbid obesity; obesity; weight regain.

PubMed Disclaimer

References

REFERENCES

    1. Athanasiadis DI, Martin A, Kapsampelis P, Monfared S, Stefanidis D. Factors associated with weight regain post‐bariatric surgery: a systematic review. Surg Endosc. 2021;35(8):4069‐4084. doi:10.1007/s00464‐021‐08329‐w
    1. Adams TD, Davidson LE, Litwin SE, et al. Weight and metabolic outcomes 12 years after gastric bypass. N Engl J Med. 2017;377(12):1143‐1155. doi:10.1056/NEJMoa1700459
    1. Brissman M, Beamish AJ, Olbers T, Marcus C. Prevalence of insufficient weight loss 5 years after Roux‐en‐Y gastric bypass: metabolic consequences and prediction estimates: a prospective registry study. BMJ Open. 2021;11(3):e046407. doi:10.1136/bmjopen‐2020‐046407
    1. Salminen P, Kow L, Aminian A, et al. IFSO consensus on definitions and clinical practice guidelines for obesity management—an international Delphi study. Obes Surg. 2024;34(1):30‐42. doi:10.1007/s11695‐023‐06913‐8
    1. Murvelashvili N, Xie L, Schellinger JN, et al. Effectiveness of semaglutide versus liraglutide for treating post‐metabolic and bariatric surgery weight recurrence. Obesity (Silver Spring). 2023;31(5):1280‐1289. doi:10.1002/oby.23736

MeSH terms